Compare Cintas Corporation (CTAS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Cintas Corporation trades at $202.49 (market cap $79.86B), while State Street SPDR S&P Biotech ETF trades at $154.09 (market cap $10.11B). The key difference: Cintas Corporation is far larger — about 7.9× State Street SPDR S&P Biotech ETF's market cap, and Cintas Corporation pays a 1.03% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 125 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| CTAS | XBI | |
|---|---|---|
Market Cap | $79.86B | $10.11B |
Volume | 1,323,583 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $216.53 | $169.55 |
52-Week Low | $163.55 | $104.99 |
Typical Hold Time | 125 Days | 38 Days |
Enterprise Value | $82.33B | — |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $202.25, up 2.57% today, reflecting strong momentum after recent earnings beats. The stock shows bullish technical signals, with price above key moving averages and support at $198. Fundamentally, Q1 2027 revenue reached $3.01 billion, a 10.9% YoY increase, with earnings per share of $1.39 beating estimates. The company raised fiscal 2027 guidance, signaling confidence in continued organic growth and margin expansion, supported by a robust business model in uniform rental and workplace services.
The outlook remains positive given upward earnings revisions and a consensus price target of $234.60, implying 16% upside. However, risks include elevated valuation multiples (P/E 39.67) and sensitivity to economic cycles affecting corporate spending. Analyst sentiment is mixed with 40% buy ratings, but institutional ownership trends and dividend growth underscore long-term stability. Execution on guidance and margin sustainability are key to maintaining premium valuation.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
